Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. MaxCyte, Inc.
  6. Summary
    MXCT   US57777K1060

MAXCYTE, INC.

(MXCT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
09/20/2021 09/21/2021 09/22/2021 09/23/2021 09/24/2021 Date
1000(c) 1030(c) 1060(c) 1032.5(c) 1000(c) Last
106 667 32 639 6 812 79 388 118 003 Volume
-6.54% +3.00% +2.91% -2.59% -3.15% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 30,3 M - -
Net income 2021 -21,0 M - -
Net cash position 2021 268 M - -
P/E ratio 2021 -59,4x
Yield 2021 -
Sales 2022 39,5 M - -
Net income 2022 -20,3 M - -
Net cash position 2022 193 M - -
P/E ratio 2022 -68,3x
Yield 2022 -
Capitalization 1 373 M 1 373 M -
EV / Sales 2021 36,5x
EV / Sales 2022 29,8x
Nbr of Employees 65
Free-Float 86,1%
More Financials
Company
MaxCyte, Inc. (MaxCyte) is a life sciences company. The Company is focused on advancing the discovery, development and commercialization of cell therapies. The Company provide cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology. MaxCyte has developed and commercialized Flow Electroporation... 
More about the company
Ratings of MaxCyte, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about MAXCYTE, INC.
09/17MAXCYTE, INC. : Results of Operations and Financial Condition, Financial Statements and Ex..
AQ
09/17MaxCyte to be Added to Russell 3000, 2000 Indices; Shares Rise Early
MT
09/17MAXCYTE : Set to Join Russell 2000« Index
AQ
09/14MAXCYTE : Widens Loss in H1 As Expenses Rise; Revenue Jumps
MT
09/14MAXCYTE : Half-year Report
PU
09/13MAXCYTE : Management's Discussion and Analysis of Financial Condition and Results of Opera..
AQ
09/13MaxCyte Logs Flat Q2 Loss, Higher Revenue
MT
09/13MAXCYTE : Reports Second Quarter and Half-Year 2021 Financial Results Provides Preliminary..
AQ
09/13MaxCyte, Inc. Provides Preliminary Revenue Guidance for the Year 2021
CI
09/13NORTH AMERICAN MORNING BRIEFING : Stock Futures -2-
DJ
09/02MAXCYTE : to Report Second Quarter 2021 Financial Results on September 13, 2021
AQ
08/24William Blair Initiates Coverage on MaxCyte With Outperform Rating
MT
08/24Stephens Starts MaxCyte at Overweight With $19 Price Target
MT
08/24Stifel Starts MaxCyte at Buy With $18 Price Target
MT
08/24BTIG Starts MaxCyte at Buy With $22 Price Target
MT
More news
News in other languages on MAXCYTE, INC.
09/17MaxCyte sera ajouté aux indices Russell 3000 et 2000 ; les actions montent rapidement
09/14MaxCyte creuse sa perte au premier semestre en raison de l'augmentation des dépenses et..
09/13MaxCyte enregistre une perte stable au deuxième trimestre et une hausse des recettes
09/13MaxCyte, Inc. fournit des prévisions de revenus préliminaires pour l'année 2021
More news
Analyst Recommendations on MAXCYTE, INC.
More recommendations
Chart MAXCYTE, INC.
Duration : Period :
MaxCyte, Inc. Technical Analysis Chart | MXCT | US57777K1060 | MarketScreener
Technical analysis trends MAXCYTE, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 13,67 $
Average target price 17,24 $
Spread / Average Target 26,1%
EPS Revisions
Managers and Directors
Douglas A. Doerfler President, Chief Executive Officer & Director
Amanda L. Murphy Chief Financial Officer
J. Stark Thompson Non-Executive Chairman
James Brady VP-Technical Applications & Customer Support
William W. Brooke Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
MAXCYTE, INC.89.57%1 373
THERMO FISHER SCIENTIFIC30.58%239 899
DANAHER CORPORATION46.32%231 660
INTUITIVE SURGICAL, INC.27.53%124 147
SIEMENS HEALTHINEERS AG42.12%78 408
EDWARDS LIFESCIENCES CORPORATION32.65%74 843